Abstract
Purpose
The aim of this study was the development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of EGFR (intravenous regimens).
Methods
Five nurses with experience in oncology created a 25-item questionnaire. The questionnaire was presented to six experts for assessment of face and content validity. Item analysis and reliability testing were evaluated on the test results of 76 nurses.
Results
Face and content validity was achieved for 25 items. Two items with low biserial correlations were deleted. The values for item difficulty range from 0.2 to 0.7. The values for item discrimination ranged from 0.25 to 0.64. The complete post-tested 23-item questionnaire showed excellent internal consistency with Kuder–Richardson 20 score of 0.909. The Cohen κ tests showed that the questionnaire has very good test–retest reliability. The specific tool can be used in several studies, leading to the development of educational interventions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12:5268
Giadiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 11(6):755–768
Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15 (Review)
Wainberg Z, Hecht JR (2006) Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther 6(11):1229–1235
Ng M, Cunningham D (2004) Cetuximab (Erbitux)—an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract 58(10):970–976
Bernier J et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19(1):142–149
European Medicines Agency. www.emea.europa.eu
Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201–1208
Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ (2009) Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 27(11):1822–1828
Lynn MR (1986) Determination and quantification of content validity. Nurs Res 35(6):382–385
Haladyna TM (1999) Developing and validating multiple-choice test items. Lawrence Erlbaum, Hillsdale
Wiersma W, Jurs SG (1990) Educational measurement and testing. Allyn & Bacon, Boston
Conflict of interest statement
This manuscript does not present a conflict of interest for the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found online at http://dx.doi.org/10.1007/s00520-013-1923-3.
Rights and permissions
About this article
Cite this article
Papageorgiou, D.K., Konsatntinidis, T., Skandalaki, N. et al. Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor. Support Care Cancer 20, 1667–1671 (2012). https://doi.org/10.1007/s00520-011-1257-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-011-1257-y